Comparative Pharmacology
Head-to-head clinical analysis: HYDRAMINE versus LORATADINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRAMINE versus LORATADINE.
HYDRAMINE vs LORATADINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antagonist of histamine H1 receptors, preventing histamine-mediated responses such as vasodilation, bronchoconstriction, and increased capillary permeability.
Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1-receptor antagonist activity. It inhibits histamine-induced vasodilation and bronchoconstriction.
50-100 mg IV/IM every 4-6 hours, maximum 400 mg per day. Also available as 50 mg oral tablets.
10 mg orally once daily
None Documented
None Documented
Terminal elimination half-life 5.7 hours, range 4.2-7.7 hours; prolonged in hepatic impairment (up to 15 hours in cirrhosis)
Clinical Note
moderateDiphenhydramine + Deferasirox
"The serum concentration of Deferasirox can be increased when it is combined with Diphenhydramine."
Clinical Note
moderateDiphenhydramine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fluticasone propionate."
Clinical Note
moderateLoratadine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Loratadine is combined with Fluticasone propionate."
Clinical Note
moderateLoratadine: 8-14 hours (mean ~10 hours). Active metabolite descarboethoxyloratadine: 17-24 hours (mean ~20 hours). Clinically, duration supports once-daily dosing.
Primarily renal (95%) as metabolites; <5% unchanged; 5% fecal
Approximately 40% excreted in urine as metabolites (primarily descarboethoxyloratadine) and 40% in feces as metabolites; <1% excreted unchanged.
Category C
Category A/B
Antihistamine
Antihistamine
Loratadine + Teriflunomide
"The metabolism of Teriflunomide can be decreased when combined with Loratadine."